<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03552289</url>
  </required_header>
  <id_info>
    <org_study_id>17-04</org_study_id>
    <nct_id>NCT03552289</nct_id>
  </id_info>
  <brief_title>Cook Enforcer Post-Market Study</brief_title>
  <official_title>Randomized Clinical Study to Evaluate the Advance® Enforcer™ 35 Focal-Force PTA Balloon Catheter in Treatment of Arteriovenous Dialysis Access Circuit Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook Research Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook Group Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the performance of the Cook Advance® Enforcer™ 35
      Focal-Force PTA Balloon Catheter (or Enforcer balloon) in treating narrowed blood vessels
      compared to treatment with a conventional angioplasty balloon.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Actual">August 27, 2019</completion_date>
  <primary_completion_date type="Actual">May 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of lesions requiring adjunctive treatment</measure>
    <time_frame>immediately following treatment of stenoses of a mature native arteriovenous dialysis access circuit fistula or graft</time_frame>
    <description>Percentage of lesions requiring adjunctive treatment immediately following the initial treatment with the Enforcer or conventional angioplasty balloon</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Cook Enforcer balloon catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional angioplasty balloon catheters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercial available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter</intervention_name>
    <description>The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula</description>
    <arm_group_label>Cook Enforcer balloon catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional angioplasty balloon catheters</intervention_name>
    <description>Commercial available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula</description>
    <arm_group_label>Conventional angioplasty balloon catheters</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical or physiological abnormalities which indicate dialysis access dysfunction
             (e.g., decreased access blood flow, elevated venous pressure, decreased dialysis dose,
             abnormal physical exam)

        Exclusion Criteria:

          -  Less than 18 years old

          -  Pregnant, lactating, or planning to become pregnant in the 3 months following
             enrollment

          -  Underwent any surgical or interventional procedure of the access circuit less than or
             equal to 30 days prior to enrollment

          -  Scheduled for a kidney transplant

          -  Stent or stent graft in the arteriovenous (AV) dialysis access circuit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Kideny Disease &amp; Hypertension Surgery Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vascular Experts</name>
      <address>
        <city>Darien</city>
        <state>Connecticut</state>
        <zip>06820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Kidney/Nephrology Associates, PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairlawn Surgery Center</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Institute of Virginia</name>
      <address>
        <city>Woodbridge</city>
        <state>Virginia</state>
        <zip>22193</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>Renal</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Stenosis(es)</keyword>
  <keyword>Transluminal</keyword>
  <keyword>Percutaneous Transluminal Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

